JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Langner, C
Right arrow Articles by Zigeuner, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Langner, C
Right arrow Articles by Zigeuner, R
Journal of Clinical Pathology 2004;57:773-775
© 2004 BMJ Publishing Group Ltd & Association of Clinical Pathologists


SHORT REPORT

Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?

C Langner1, M Ratschek1, P Rehak2, L Schips3, R Zigeuner3

1 Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria
2 Department of Surgery, Division of Biomedical Engineering and Computing, Medical University of Graz
3 Department of Urology, Medical University of Graz

Correspondence to:
Dr C Langner
Institute of Pathology, Medical University of Graz, Auenbruggerplatz 25, A-8036 Graz, Austria; cord.langner{at}meduni-graz.at
ABSTRACT
Aims: To assess whether heterogeneity of epidermal growth factor receptor (EGFR) immunoreactivity in renal cell carcinoma (RCC) is related to non-standardised criteria for staining evaluation.

Methods: EGFR expression was investigated in 132 primary and 55 metastatic conventional RCCs using a tissue microarray technique.

Results: Overall, membranous and/or cytoplasmic EGFR immunostaining was present in 123 of 132 (93%) primary and 49 of 53 (92%) metastatic RCCs, with extensive immunoreactivity (> 50% of tumour cells) in 110 of 132 (83%) primary tumours and 39 of 53 (73%) metastases. Cytoplasmic staining was associated with high tumour stage and high tumour grade. In addition, strong membranous staining (score 3+) prevailed in high grade RCCs. Cytoplasmic immunostaining was associated with an unfavourable prognosis, whereas overall (cytoplasmic and membranous) immunoreactivity and intensity of membranous staining were not.

Conclusions: Different methods of immunohistochemical evaluation led to different results, strengthening the need for standardisation, especially against a background of rapidly evolving EGFR targeted cancer treatment strategies.


Abbreviations: EGFR, epidermal growth factor receptor; RCC, renal cell carcinoma

Keywords: renal cell carcinoma; epidermal growth factor receptor; immunohistochemical evaluation; prognosis; treatment




This article has been cited by other articles:


Home page
Ann OncolHome page
P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
Ann. Onc., August 1, 2006; 17(8): 1185 - 1196.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2004 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.